奈达铂联合紫杉醇在宫颈癌同步放化疗中的应用

Application of nedaplatin and paclitaxel in the concurrent radiochemotherapy of cervical carcinoma

  • 摘要: 目的:研究分析同步放化疗奈达铂联合紫杉醇治疗宫颈癌的临床疗效。方法随机分组为对照组和观察组,各32例,在同样放疗基础上,观察组给予奈达铂、紫杉醇治疗,治疗结束后评价其有效率和不良反应。结果对照组总有效率为65.6%,观察组总有效率为75.0%,2组治疗总有效率无显著差异。2组患者均出现了不同程度的不良反应,观察组不良反应发生率高于对照组。观察组患者总生存率(OS)、无远处转移生存率(DMF)、明显高于对照组。结论奈达铂联合紫杉醇方案同步放化疗对宫颈癌治疗临床疗效明显,且毒性低,值得临床上扩大病例进一步研究。

     

    Abstract: Objective To study the clinical efficacy of nedaplatin and paclitaxel in patients with cervical carcinom by concurrent radiochemotherapy.Methods A total of 64 patients were ran-domly divided into control group given radiotherapy and observation group added with nedaplatin and paclitaxel with 32 patients in each group.The clinical efficacy and adverse reactions in both groups were evaluated after treatment.Results The clinical efficacy of control group was 65.6%which was lower than that of observation group (75.0%),the difference was not significant.How-ever,the rate of adverse reactions,the overall survival (OS)and the distant metastasis-free survival (DMF)were higher in observation group than that in the control group.Conclusion Concurrent radiochemotherapy with treatment of nedaplatin and paclitaxel is remarkably efficient with low toxi-city in treating cervical carcinoma,so it is worthy of being further studied and promoted in clinic.

     

/

返回文章
返回